SfN 2024: Where neuroscience meets community, collaboration, and innovation

As Ab­b­Vie con­tin­ues to tout its next gen­er­a­tion of im­munol­o­gy drugs be­hind Hu­mi­ra, it’s buy­ing an ear­ly-stage start­up to boost its longer-term prospects in in­flam­ma­to­ry

BMS added Krazati to its portfolio when it acquired Mirati Therapeutics for $5.8bn. Credit: Katherine Welles/Shutterstock. The US Food and Drug Administration (FDA) has approved

“Nearly all pediatricians encounter parents who want to do what is best for their child — even though it may mean they have questions about